Vishal C Patel

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/773483/vishal-c-patel-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 1,423 17 37 h-index g-index citations papers 1,892 6.5 4.41 59 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
38	Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices <i>PLoS ONE</i> , 2022 , 17, e0263288	3.7	O
37	Images of the month 1: Histoacryl glue embolisation to the right ventricle following treatment for gastric varices <i>Clinical Medicine</i> , 2022 , 22, 163-164	1.9	
36	The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 668459	5.7	O
35	Prevalence of bleeding and thrombosis in critically ill patients with chronic liver disease. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
34	Hemostatic balance in acute-on-chronic liver failure. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 869-870	15.4	
33	Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation. <i>Hepatology</i> , 2021 , 74, 907-925	11.2	5
32	Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 85-95	15.4	13
31	Rifaximin-Ireduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. <i>Journal of Hepatology</i> , 2021 ,	13.4	11
3 0	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 834-843	15.4	8
29	Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis. <i>Clinical Medicine</i> , 2020 , 20, 493-500	1.9	1
28	Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival. <i>Hepatology</i> , 2020 , 71, 1381-1390	11.2	33
27	Antimicrobial resistance in chronic liver disease. Hepatology International, 2020, 14, 24-34	8.8	9
26	Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Reports, 2020 , 2, 100151	10.3	8
25	Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 435-441	6.1	26
24	Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF. <i>JHEP Reports</i> , 2019 , 1, 179-187	10.3	10
23	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal microbiota Transplantation in cirrhosis: study protocol for a single-blinded trial. <i>BMJ Open</i> , 2019 , 9, e023518	3	21
22	P: 12 PROFIT: PROspective, Randomised Placebo-controlled Feasibility Trial of Faecal Microbiota Transplantation in Cirrhosis Interim Analysis. <i>American Journal of Gastroenterology</i> , 2019 , 114, S5-S7	0.7	1

(2015-2019)

21	P: /1 Faecal Cytokine Profiling Provides Novel Insights Into Intestinal Barrier Disruption and Bacterial Translocation in Acute Decompensation of Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019 , 114, S36-S37	0.7	1
20	Platelet-leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1375-1386	6.1	11
19	MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. <i>Gut</i> , 2018 , 67, 333-347	19.2	88
18	CD14 CD15 HLA-DR myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. <i>Gut</i> , 2018 , 67, 1155-1167	19.2	57
17	Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 192-202	6.1	101
16	Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. <i>Journal of Critical Care</i> , 2018 , 43, 54-60	4	61
15	Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. <i>Gut</i> , 2018 , 67, 918-930	19.2	71
14	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. <i>Journal of Clinical Apheresis</i> , 2018 , 33, 638-644	3.2	4
13	In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. <i>Liver International</i> , 2018 , 38, 1988-1996	7.9	23
12	High-Speed Quantitative UPLC-MS Analysis of Multiple Amines in Human Plasma and Serum via Precolumn Derivatization with 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate: Application to Acetaminophen-Induced Liver Failure. <i>Analytical Chemistry</i> , 2017 , 89, 2478-2487	7.8	51
11	High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. <i>Journal of Hepatology</i> , 2016 , 64, 69-78	13.4	307
10	Clinical science workshop: targeting the gut-liver-brain axis. <i>Metabolic Brain Disease</i> , 2016 , 31, 1327-133	3 73.9	16
9	Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. Journal of Hepatology, 2016 , 64, 1058-1067	13.4	55
8	Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure. <i>Critical Care Medicine</i> , 2016 , 44, 43-53	1.4	16
7	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-[]Liver International, 2016 , 36, 1295-303	7.9	35
6	Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. <i>Gastroenterology</i> , 2015 , 148, 603-615.e14	13.3	148
5	Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure-Sequential Organ Failure Scoring System. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1353-1360.e8	6.9	65
4	Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. <i>Immunotherapy</i> , 2015 , 7, 641-54	3.8	25

3	Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. <i>Analytical Chemistry</i> , 2015 , 87, 9662-70	7.8	120
2	OC-029 Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience. <i>Gut</i> , 2014 , 63, A14.2-A15	19.2	2
1	Diabetes and the gastrointestinal tract. <i>Medicine</i> , 2011 , 39, 288-292	0.6	4